Foretinib, also known as EXEL-2880, XL880, and GSK1363089, is an experimental drug candidate for the treatment of cancer, is a small-molecule inhibitor of the hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) receptor tyrosine kinase families. Foretinib caused mitotic catastrophe in chronic myelogenous leukemia cells and other cell lines. Foretinib (GSK1363089, XL880) is an inhibitor of MET and VEGFR2, which are believed to play cooperative roles in promoting tumor growth and angiogenesis.; Purity: > 99% pure; Molecular Weight: 632.65 g/mol, 50 mg